Massachusetts is currently home to 3215 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Cognitive Processing Therapy (CPT) Memory Support (MS) Study
NCT05310097
Recruiting
The efficacy of psychological interventions for posttraumatic stress disorder (PTSD) is likely limited by the difficulty participants have learning and remembering important therapy content. Accordingly, the present study will examine the utility of integrating a Memory Support (MS) intervention into Cognitive Processing Therapy (CPT), an empirically supported and widely disseminated treatment for PTSD. MS was designed to integrate techniques aimed at facilitating encoding, consolidation, and re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: VA Boston Healthcare System, Jamaica Plain, Massachusetts
Conditions: PTSD
Register for Updates
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
NCT04637763
Recruiting
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
Register for Updates
Leniolisib for Immune Dysregulation in CVID
NCT06897358
Recruiting
In this study, common variable immunodeficiency (CVID) patients will all receive the study drug, leniolisib, for a treatment period of 6 months. Participants will start on a lower dose of leniolisib, followed by a mid and then a higher dose level. The primary goal is to assess the safety and tolerability of leniolisib, and secondary goal is to assess the potential for leniolisib to provide benefits for patients.
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
03/20/2025
Locations: Lahey Hospital & Medical Center, Burlington, Massachusetts
Conditions: Common Variable Immunodeficiency (CVID)
Register for Updates
Multisite Virtual Reality Intervention for Speech Anxiety
NCT06593847
Recruiting
Exposure-based cognitive behavior therapy is an efficacious treatment for speech anxiety and has been delivered effectively in a virtual reality (VR) environment. The present multicenter study (conducted through the Exposure Therapy Consortium) is designed to evaluate whether trait versus state positive affectivity is a more effective predictor of exposure therapy outcomes. Further, the investigators will examine whether the predictive significance of trait positive affectivity can be accounted... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/20/2025
Locations: Tufts University, Boston, Massachusetts
Conditions: Public Speaking, Speech Anxiety
Register for Updates
EIM Via the Myolex MScan As an ALS Biomarker
NCT06491732
Recruiting
Amyotrophic lateral sclerosis (ALS) has been traditionally considered incurable and untreatable. But starting in the 1990s with the introduction of Riluzole, therapies are being discovered and ultimately approved for slowing disease progression. Many pharmaceutical companies continue to seek new therapeutic approaches. One critical aspect of all clinical trials is the need track to progression sensitively to identify the impact of therapy. Tools to track ALS progression must be convenient, objec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Sauna for Long Covid
NCT05931497
Recruiting
Research suggests that Whole Body Hyperthermia in a sauna-like environment can reduce symptoms related to post-acute sequelae of SARS-CoV-2 (PASC), or Long Covid. The investigators aim to study the feasibility and treatment effect of this procedure for patients experiencing Long Covid symptoms.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/20/2025
Locations: Depression Clinical and Research Program, Boston, Massachusetts
Conditions: Long COVID
Register for Updates
Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT05467891
Recruiting
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Register for Updates
A Study of YL201 in Patients with Advanced Solid Tumors
NCT05434234
Recruiting
This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors unresponsive to currently available therapies or for whom no standard therapy is available. Part 2 will include patients with selected advanced solid tumor t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Mass General Cancer Center: Hematology, Boston, Massachusetts
Conditions: Advanced Solid Tumor
Register for Updates
STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors
NCT05098132
Recruiting
This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
Register for Updates
Study to Evaluate VT3989 in Patients with Metastatic Solid Tumors
NCT04665206
Recruiting
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in 3- or 4-week cycles in patients with mesothelioma and/or metastatic solid tumors that are resistant or refractory to standard therapy or for which no effective standard therapy is available.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Solid Tumor, Adult, Mesothelioma, NSCLC
Register for Updates
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
NCT06864143
Recruiting
The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/19/2025
Locations: DM Clinical Research - Boston, Brookline, Massachusetts
Conditions: Influenza, SARS-CoV-2
Register for Updates
Mind Body Intervention for Chronic Migraine Headaches
NCT06690060
Recruiting
The goal of this exploratory study is to test a mind-body interventional approach for the treatment of chronic migraines. The main goal is to obtain feasibility information on the protocol which has been used in other similar conditions. We will also evaluate multiple measurement tools in order to optimize a follow-up pilot study evaluating the impact of the protocol on migraines.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Migraines, Chronic Pain
Register for Updates